These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22205396)

  • 1. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
    Chang MY; Ong AC
    Nephron Clin Pract; 2012; 120(1):c25-34; discussion c35. PubMed ID: 22205396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Slow the pace of renal failure in autosomal dominant polycystic kidney disease: hopes and disappointments].
    Burtey S
    Presse Med; 2011 Nov; 40(11):1059-64. PubMed ID: 21964037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
    Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?
    Kou P; Wei S; Xiong F
    Curr Med Chem; 2019; 26(16):2962-2973. PubMed ID: 29600752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug therapy for polycystic kidney disease: a review and perspective.
    Aguiari G; Catizone L; Del Senno L
    Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.
    Santoro D; Pellicanò V; Visconti L; Trifirò G; Buemi M; Cernaro V
    Expert Opin Investig Drugs; 2015; 24(9):1199-218. PubMed ID: 26125126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better understanding of ADPKD results in potential new treatment options: ready for the cure?
    Meijer E; de Jong PE; Peters DJ; Gansevoort RT
    J Nephrol; 2008; 21(2):133-8. PubMed ID: 18446706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of autosomal dominant polycystic kidney disease].
    Torra R
    Med Clin (Barc); 2014 Jan; 142(2):73-9. PubMed ID: 24246705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management.
    Mallett A; Lee VW; Mai J; Lopez-Vargas P; Rangan GK
    Semin Nephrol; 2015 Nov; 35(6):582-589.e17. PubMed ID: 26718162
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.
    Rysz J; Gluba-Brzózka A; Franczyk B; Banach M; Bartnicki P
    Expert Opin Pharmacother; 2016 Oct; 17(15):2049-56. PubMed ID: 27650472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
    Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
    Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to inhibit cyst formation in ADPKD.
    Calvet JP
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1205-11. PubMed ID: 18434615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options in the treatment of autosomal dominant polycystic kidney disease.
    Kazancioglu R; Gursu M
    Ren Fail; 2015 May; 37(4):535-41. PubMed ID: 25682970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Polycystic kidney disease].
    Higashihara E
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():83-90. PubMed ID: 17899832
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.